The adaptive behavior codes were written for more than autism. Commercial payers, Virginia and now a CMS toolkit are drawing the coverage line at F84.0.
Key Takeaways
- The coverage gap: The field’s own model coverage template supports treatment for intellectual disability, ADHD, feeding disorders and brain injury, yet most payer policies pay only on an autism diagnosis.
- The federal push: CMS’s August toolkit asks states to reserve ongoing ABA benefits for children whose autism has been formally confirmed, and Virginia has already put that rule in its budget.
- The money already moving: Medicaid and CHIP paid $1.47 billion in 2025, 14.5 percent of ABA spending, for services to treat conditions other than autism.
- The narrow path: EPSDT still requires medically necessary care for children regardless of diagnosis, so non-autism ABA will depend on condition-specific evidence and documentation.
Midway through the ABA Coding Coalition’s model coverage policy, a two-column table lists the diagnoses the coalition says support medical necessity for applied behavior analysis. Autism appears there, between specific learning disorders and global developmental delay. So do dementia, avoidant/restrictive food intake disorder, Tourette and tic disorders, pica, encopresis, selective mutism and intracranial injury. Beneath the table sits a line that reads like a note from a claims department: “Use of any ICD-10-CM code not listed here in authorization requests or claims may result in denial.”
Members of the coalition, including the Association of Professional Behavior Analysts, Autism Speaks, the certification board for the field and the Council of Autism Service Providers, wrote the document as a template for Medicaid agencies, TRICARE and commercial insurers. Its table describes a discipline considerably wider than the market that pays for it. Most coverage for ABA arrived through state autism insurance mandates, and most payer policies still treat the service and the diagnosis as a single unit. That arrangement is now being pressed from two sides. Federal regulators want the autism requirement applied more consistently, and operators absorbing rate cuts are asking whether any other patient population is open to them.
What the Adaptive Behavior Codes and Model Coverage Policy Cover
The CPT codes themselves, 97151 through 97158 plus two Category III codes for destructive behavior, describe procedures and the professionals who perform them. They name assessments, technician-delivered treatment, protocol modification and family guidance, and their descriptors do not specify a diagnosis. That question belongs to payers. Its own answer, first published in September 2020 and updated in January 2022 with additional diagnostic codes, is that ABA is effective for disorders arising during the developmental period, which “include but are not limited to autism spectrum disorder, intellectual and other developmental disabilities, attention-deficit/hyperactivity disorder, brain injuries and diseases, movement disorders, feeding disorders, and behavior disorders.”
Comprehensive programs, often 30 to 40 hours a week, are distinguished in the policy from focused treatment aimed at a handful of targets such as self-injury, elopement or feeding. Focused treatment, the document says, “is not restricted by age, cognitive level, diagnosis, or co-occurring conditions.” Its bibliography reaches well outside autism to support that position. Among the cited work is a 2010 quantitative synthesis of pediatric feeding disorder treatment by Sharp and colleagues in Clinical Child and Family Psychology Review and a 2009 randomized trial of a specialist behavior therapy team for adults with intellectual disabilities by Hassiotis and colleagues in the American Journal of Psychiatry.
How Payers Limit ABA Coverage to an Autism Diagnosis
Insurers read the same literature differently. Aetna’s clinical policy bulletin on applied behavior analysis states that the company considers ABA “experimental, investigational, or unproven for all other non-ASD indications because of insufficient evidence in the peer-reviewed literature,” and it singles out Down syndrome without co-occurring autism as one such indication. That position fits the way the benefit was assembled. CMS’s new toolkit attributes part of the growth in ABA spending to ABA “being a mandated service for fully insured, state-regulated health plans,” and those mandates were written around autism.
Medicaid programs keep their own versions of the line, and Virginia moved its version into statute this year. Item 291.WW.2 of the 2026 Appropriation Act, summarized in a Department of Medical Assistance Services bulletin on July 28, provides that “the department shall require a diagnosis of autism spectrum disorder prior to authorizing ABA services,” with a one-year provisional diagnosis available for children age five and younger. Alongside it sits the 20-hour weekly cap Acuity examined in August. DMAS says it will announce an effective date for both changes after CMS approves the necessary state plan changes.
CMS Toolkit Ties Sustained ABA Coverage to a Confirmed Autism Diagnosis
The federal government weighed in on August 4. The State Medicaid and CHIP Applied Behavior Analysis Toolkit runs past 170 pages and, by its own description, is guidance rather than regulation. Its data chapter reports that Medicaid and CHIP payments for ABA rose from about $1.94 billion in 2021 to $10.1 billion in 2025, an increase of 421 percent. Buried in that chapter is a figure that bears directly on the diagnosis question. In 2025, CMS writes, “$1.47 billion, or 14.5 percent of all Medicaid and CHIP ABA spending, was paid for ABA services to treat other conditions,” and the agency names ADHD as an example. A full appendix is devoted to ABA for individuals without autism.
The toolkit’s recommendation on eligibility is direct. In a passage marked as best practice, CMS says states “should tie sustained ABA coverage to a confirmed ASD diagnosis,” while allowing that some states may authorize limited, time-bound services under EPSDT when autism is strongly suspected and an evaluation is pending. Those interim uses, the agency adds, “should be tightly defined and not substitute for diagnosis-driven treatment.” That concern has a paper trail, since the HHS Office of Inspector General’s Indiana audit found services delivered to children who had never received the required diagnostic evaluation, as Acuity noted in its coverage of Indiana’s reform bulletin and the broader OIG audit series.
Elsewhere the document is less categorical. Describing how providers set the scope of a treatment plan, it states: “Decisions on scope of treatment should not be restricted by an individual’s age, co-occurring conditions, ASD diagnosis, or cognitive level.” That sentence concerns the design of care for children already in the benefit, not who qualifies for it. The toolkit also acknowledges what waiting for a diagnosis costs, citing a 2023 analysis in The Journal of Pediatrics by Chen and colleagues on the delay between screening and diagnosis and noting that some families wait two years.
EPSDT Sets a Legal Floor for Non-Autism Behavioral Treatment
For children enrolled in Medicaid, the diagnosis rule runs into a federal entitlement built around medical necessity rather than diagnosis labels. Early and Periodic Screening, Diagnostic, and Treatment obligates states to cover medically necessary services under section 1905(a) of the Social Security Act for beneficiaries under 21, whether or not the state plan covers them for adults. The coalition’s model policy spells out the consequence: “Hard, fixed, or arbitrary limits (e.g., based on dollar amounts, standard deviations from the norm, lists of diseases) are not permitted.” CMS’s 2014 informational bulletin on autism services clarified how EPSDT applies to children with autism, guidance the toolkit credits with part of ABA’s Medicaid growth. Other diagnoses were outside its scope.
The toolkit restates the principle for co-occurring conditions: “Diagnosis and treatment of diseases, conditions, and disorders should be conducted independently of the ASD diagnosis and should follow clinical guidelines and EPSDT requirements.” In practice, a child with an intellectual disability and severe self-injury but no autism diagnosis has a route to behavioral treatment that runs through individual medical necessity review rather than a standing ABA benefit. Judging by the $1.47 billion figure, that route is used at considerable scale, and it covers a slice of spending the toolkit’s own recommendations would bring under closer review.
Why ABA Diversification Runs Into the Billing Infrastructure
For operators, the question has turned practical. Rates are falling in several markets. Indiana is phasing its Medicaid ABA rates down by roughly 10 percent in two steps across 2026 and 2027, and a Georgia managed care plan notified providers of a 20 percent cut. Expanding into feeding disorders, adult developmental disability services or neurorehabilitation is an obvious response on paper, and the professional base is large enough to attempt it. By the certification board’s July 1 count, 85,587 people held the Board Certified Behavior Analyst credential, supported by a technician workforce of more than 260,000.
Most of the obstacles sit in the plumbing. Authorization templates, medical record configurations and managed care credentialing files at most ABA organizations are organized around an autism diagnosis, because that is what most payers require. Carriers that do cover other conditions tend to want condition-specific evidence of medical necessity, and an insurer that classifies non-autism ABA as unproven will pay only through an exception or appeal. The 2027 revisions to the adaptive behavior code set change how services are described and billed. Coverage policy, not the CPT book, still decides which diagnoses a given payer will accept.
Outcome measurement adds a further layer. CMS urges states to require standardized outcome instruments and to reject provider-created measures, and most of its examples are built for young children with autism, although one, Essential for Living, is listed as appropriate for children and adults. Organizations serving other populations will need outcome data that holds up for each condition they treat, a gap Acuity explored in its reporting on ABA outcomes data at scale.
What ABA Providers Can Document as States Decide
Virginia’s state plan filing and the accompanying manual update will show how its provisional diagnosis pathway and EPSDT exceptions work in daily authorization, and other Medicaid agencies working through the toolkit’s checklists will decide whether their share of non-autism ABA spending represents appropriate EPSDT care or a category to curtail. Commercial carriers will continue to set their own terms plan by plan.
For providers, the documents point toward a narrow, evidence-driven version of diversification rather than a broad expansion. Tracking the diagnosis mix within an existing caseload is the starting point, since the share of non-autism patients is the figure an auditor or managed care plan will ask about first. Serving children whose diagnoses fall outside F84.0 then depends on condition-specific medical necessity records, paired with peer-reviewed support for each indication and a working knowledge of how EPSDT review operates in each state.
The coalition’s table of qualifying diagnoses has stood since its January 2022 update. Virginia’s effective date, and the toolkit’s reception in other state capitals, will determine how much of that table payers are prepared to honor.
